Harrison D C, Lippincott J R
Consultant. 1988 Mar;28(3):82-3, 87-8, 91.
The cost of caring for patients with cardiovascular disease has increased more than 50% in the past five years. Much of this increase is due to the dissemination of new technologies that have proved effective for specific patient populations. Molecular biology, immunology, magnetic resonance imaging, and second generation cardiovascular drugs all promise more effective, noninvasive diagnostic and treatment methods--and continued higher costs. To avoid extreme solutions to cost-increase problems, results of clinical research must be better utilized to determine indications for high-cost procedures. Also important are improved methods of evaluating new technologies before dissemination; regionalization of high-cost services; and increased use of clinical data bases and sophisticated computer data handling, which furnish cost-effectiveness studies and tools for clinical decision-making.
在过去五年中，照顾心血管疾病患者的费用增长了超过50%。这种增长很大程度上是由于新技术的传播，这些新技术已被证明对特定患者群体有效。分子生物学、免疫学、磁共振成像和第二代心血管药物都有望带来更有效、无创的诊断和治疗方法——以及持续的更高成本。为了避免对成本增加问题采取极端解决方案，必须更好地利用临床研究结果来确定高成本程序的适应症。同样重要的是在新技术传播之前改进评估方法；高成本服务的区域化；以及更多地使用临床数据库和复杂的计算机数据处理，这为成本效益研究和临床决策提供了工具。
